Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval

Simply Wall St.07-06

AdvertisementWhy the Haystack MRD approval matters for Quest Diagnostics stock Quest Diagnostics (DGX) just received New York State approval for its Haystack MRD liquid biopsy test, clearing clinical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649861526?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-07-06 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649861526","market":"sg","top_or_hot":-1,"title":"Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the Haystack MRD approval matters for Quest Diagnostics stock Quest Diagnostics (DGX) just received New York State approval for its Haystack MRD liquid biopsy test, clearing clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-dgx-could-be-4-undervalued-on-haystack-mrd\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 00:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-dgx-could-be-4-undervalued-on-haystack-mrd><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the Haystack MRD approval matters for Quest Diagnostics stock Quest Diagnostics (DGX) just received New York State approval for its Haystack MRD liquid biopsy test, clearing clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-dgx-could-be-4-undervalued-on-haystack-mrd\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DGX","symbol_name":"奎斯特诊疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-dgx-could-be-4-undervalued-on-haystack-mrd","article_id":"2649861526","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-dgx-could-be-4-undervalued-on-haystack-mrd","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649861526","pubTimestamp":1783268094,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the Haystack MRD approval matters for Quest Diagnostics stock\nQuest Diagnostics (DGX) just received New York State approval for its Haystack MRD liquid biopsy test, clearing clinical use across all 50 states and expanding the company’s reach in advanced cancer diagnostics.\nSee our latest analysis for Quest Diagnostics.\nAlongside the Haystack MRD approval and Attunio Health partnership, Quest Diagnostics shares have climbed, with a year to date share price return of 24.13% and a 5 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DGX":"奎斯特诊疗","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","BK4196":"保健护理服务","BK4567":"ESG概念","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","BK4585":"ETF&股票定投概念","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4583":"猴痘概念","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4588":"碎股","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC"},"translate_title":"Quest Diagnostics(DGX)在Haystack MRD批准后可能被低估4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1.5},"content_text":"AdvertisementWhy the Haystack MRD approval matters for Quest Diagnostics stock Quest Diagnostics (DGX) just received New York State approval for its Haystack MRD liquid biopsy test, clearing clinical use across all 50 states and expanding the company’s reach in advanced cancer diagnostics. See our latest analysis for Quest Diagnostics. Alongside the Haystack MRD approval and Attunio Health partnership, Quest Diagnostics shares have climbed, with a year to date share price return of 24.13% and a 5 year total shareholder return of 75.34%, suggesting momentum has been building rather than fading. If this kind of healthcare testing story interests you, it could be a good moment to widen your watchlist using our screener of 40 healthcare AI stocks With Quest Diagnostics trading close to its analyst price target and carrying a solid value score, the key question now is whether Haystack MRD and new partnerships leave further upside on the table, or if the market is already pricing in future growth. Most Popular Narrative: 3.5% Undervalued With Quest Diagnostics last closing at $215.72 versus a narrative fair value of $223.44, the current setup frames the stock as modestly undervalued and puts extra focus on what is driving that gap.  Increased adoption of automation, digitization, and artificial intelligence in laboratory operations is yielding productivity improvements and cost savings, contributing to margin expansion and enhancing future operating income and net earnings. Strategic execution on accretive acquisitions including the large LifeLabs deal and expanded health system partnerships (e.g., with Fresenius) are boosting patient volumes, expanding geographic reach, and producing procurement and operational synergies that are expected to materially lift revenue and earnings.  Read the complete narrative. Want to see what sits behind that earnings and margin story? The narrative leans on measured revenue growth, rising profitability, and a future earnings multiple that still assumes discipline. Result: Fair Value of $223.44 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to factor in risks, as possible cuts to Medicare reimbursement and rising wage and technology costs are both capable of pressuring the Quest Diagnostics story. Find out about the key risks to this Quest Diagnostics narrative. Next Steps Balancing these rewards and risks around Quest Diagnostics, do you want to rely on others' sentiment or ground your view in the data yourself? Take a closer look at the full breakdown of 4 key rewards and 1 important warning sign Looking for more investment ideas beyond Quest Diagnostics? If you are serious about building a stronger portfolio, do not stop with Quest Diagnostics. Use these focused stock ideas to spot opportunities others might overlook.  Zero in on quality at a discount by scanning our universe of 44 high quality undervalued stocks that pair fundamentals with attractive pricing. Strengthen your income stream by reviewing 7 dividend fortresses that offer higher yields with supporting metrics. Protect your downside by filtering for 74 resilient stocks with low risk scores backed by healthier balance sheets and lower risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Quest Diagnostics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649861526","isCrawlerRequest":true}